under the influence of chemotaxis-inducing growth factors. During the migration, AoSMCs have been shown to digest major extracellular barriers, such as basal membranes, interstitial collagens, and proteoglycans [9] .
It is well known that the onset of vascular pathologies increases with aging and, interestingly, even AoSMCs change their gene expression pattern and their ECM composition during aging, exerting direct effects on various cellular events and cell migration [10] . In fact, a role for HA during AoSMC migration was recently established and, therefore, its possible involvement in vascular pathology [10] . In recent papers, it was demonstrated that the AoSMCs produce large amounts of HA [11] and that the ECM strongly influences cell migration [12] . The data obtained on HA synthesis in AoSMCs during aging confirm the idea that the ECM modification can alter cell migration. In vitro, aged cells produced more HA and its receptor CD44 on the cell membrane. In this in vitro aging model, primary AoSMCs were cultured for several population doublings and cells with a high number of mitosis were considered aged. The robustness of this study was achieved by measuring several markers of senescence (as P16 and galactosidase activity) and verifying the phenotype of cells during the senescence process in vitro. The role of HA and its receptor CD44 on AoSMC motility was demonstrated as blocking CD44 activity. In fact, experiments that carried out blocking the receptor or its signal transmission (the ERK1/2 phosphorylation) abolished the HA effect on cell motility [10] . Moreover, modifying the HA content in the cells by adding HA of different molecular size to the cell culture at different concentrations increased cell motility. In fact, the HA size is critical for this modulation as low-molecular-weight HA does not show the same effect observed using high-molecular-weight HA. However, as other pathways involving VCAM and ICAM proteins could potentially control the migratory capability of AoSMCs, the involvement of VCAM and ICAM throughout the evaluation of the expression in young and aged AoSMCs of these molecules was ruled out. Therefore, HA, through CD44 and ERK phosphorylation, was shown to control AoSMC migration. These experiments demonstrate that the interaction of HA and cell receptor CD44 is critical in the AoSMC motility, highlighting the role of the microenvironment in cell migration [10, 11, 12] .
In the literature, it was shown that the amount of HA increases during the early arteriosclerotic process, indicating that this polymer could play a critical role in this process [13] . In the model of aged AoSMCs, it was demonstrated that HA production, as well as the synthesis of its receptor CD44 [9] , increased and that the accumulation of HA in AoSMCs is specific, as the other GAGs did not increase their amount during in vitro aging. The analysis of AoSMC cell motility in aged cells demonstrated that the increased HA induces a higher motility and that this phenomenon was CD44 dependent. It is known that CD44 promotes arteriosclerosis [14] and that AoSMC migration during aging depends on HA, CD44, and the phosphorylation of MAP kinase ERK 1/2. Because CD44 signaling can modify the activity of the extracellular signal-related kinase ERK 1/2 [15] , the high CD44 expression in aged cells could mediate higher levels of phosphorylated ERK1/2 protein. Hence, CD44 and RHAMM (another HA receptor) can influence AoSMC behavior [16, 17] ; the expression of CD44 was significantly increased in both aged AoSMCs as well as in adult human aorta RNA [9] , supporting the idea that the in vitro cell model of AoSMCs resembles an in vivo condition [10] . It was reported that CD44-modulating cell motility could play a role in several pathologies [18] .
Considering the role of HA in the AoSMC migration, it may be reasonable to assume that the inhibition of HA synthesis in vivo in the vascular tissue may contribute to reduction of the cell migration. 4-Metyllumbelliferone (4-MU), a well-known HA synthesis inhibitor [19] , could be considered as a candidate for drug-eluting stents in order to prevent cell migration and, in final extent, the vessel restenosis. Moreover, other approaches are available in therapy to inhibit restenosis, as drug-eluting stents that release sirolimus or paclitaxel that arrest SMC cell cycle and migration [20] . Recently, sirolimus has been discovered to inhibit vascular SMC HA secretion [21] and the role of hyaluronan synthases expression was related to the monocyte adhesion in SMC [22] . By reducing HA synthesis and therefore the AoSMC motility, 4-MU could represent a new molecule with additional beneficial pharmacological effects in vivo.
